Celiac disease represented a significantly underserved patient population with complex, multidimensional needs that went far beyond the pharmacological. Takeda needed a structured innovation framework for identifying where it could create the most meaningful patient value — across both therapeutic and non-therapeutic dimensions of care.
Vivaldi conducted comprehensive patient and stakeholder research to map the celiac disease experience, identifying six distinct The Opportunity areas and five innovation platform concepts that could guide Takeda's development priorities. The framework addressed the full spectrum of patient needs — from diagnosis to dietary management to therapeutic intervention.
Takeda received a structured innovation roadmap with six priority The Opportunity areas and five validated platform concepts — giving the company a clear, patient-centered framework for directing R&D and commercial investment in the celiac disease space.
Takeda engaged Vivaldi to build a structured innovation framework for celiac disease, an underserved patient population with needs that extend well beyond pharmacological treatment. Vivaldi conducted patient and stakeholder research that mapped the full celiac experience from diagnosis through dietary management, identifying six opportunity areas and five innovation platforms that guide Takeda’s R&D and commercial investment priorities in the category.
Takeda Pharmaceutical Company is a global, values-based biopharmaceutical leader headquartered in Tokyo, Japan, with revenues exceeding ¥4 trillion and operations in over 80 countries. One of the world’s top 15 pharmaceutical companies, Takeda focuses on innovative medicines across oncology, rare diseases, neuroscience, and gastrointestinal conditions. The company employs approximately 50,000 people and is listed on the Tokyo and New York Stock Exchanges.
Vivaldi delivered a patient-centered innovation roadmap with six prioritized opportunity areas and five validated platform concepts that span therapeutic, diagnostic, and supportive care dimensions of celiac disease. The framework gives Takeda a structured basis for directing R&D and commercial investment in a category where patient needs had not previously been mapped end to end.
The team conducted patient and stakeholder research that mapped the full disease experience, from the long path to diagnosis through ongoing dietary management and the points where therapeutic intervention could change outcomes. That end-to-end view is what surfaced opportunities outside the strict pharmacological frame, which is where most existing celiac research had been concentrated.
In conditions like celiac where patients spend most of their time managing the disease themselves rather than receiving treatment, the unmet need sits as much in diagnosis, daily life, and information as in molecules. A pharmaceutical company that frames its opportunity purely around drug development misses the platforms that touch the patient most often, which are also the platforms that build the trust pharmacological products eventually need.
The lesson is that innovation roadmaps in underserved disease areas are stronger when they start with the patient journey rather than with the pipeline, because the journey reveals platform opportunities that pipeline-first thinking systematically overlooks. A framework that names six opportunity areas and five platforms in a single document forces strategic choice across both therapeutic and non-therapeutic options, which is usually where the most defensible positions in a category are built.